RDS03-94
Experimental drug for stimulant use disorder
From Wikipedia, the free encyclopedia
RDS03-94, or RDS3-094, is an atypical dopamine reuptake inhibitor that was derived from the wakefulness-promoting agent modafinil.[1][2][3][4]
| |
| Clinical data | |
|---|---|
| Other names | RDS3-094 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C24H32F2N2OS |
| Molar mass | 434.59 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
It has substantially higher affinity and potency in terms of dopamine transporter (DAT) inhibition than modafinil (Ki = 39.4 nM vs. 8,160 nM) whilst retaining the atypical DAT blocker profile of modafinil.[1][2] However, RDS03-94 also has high affinity for the sigma σ1 receptor (Ki = 2.19 nM).[2]
RDS03-94 shows some reversal of tetrabenazine-induced motivational deficits in animals and hence may have the capacity to produce pro-motivational effects.[5][6] However, it appears to be less effective than certain other related agents, like JJC8-088.[6][5]
RDS03-94 is under development for the treatment of psychostimulant use disorder.[1] The drug was first described in the scientific literature in 2020.[1][2]
